ISOFOL Stock Overview
A clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Isofol Medical AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 3.10 |
52 Week High | SEK 3.22 |
52 Week Low | SEK 0.45 |
Beta | 2.05 |
11 Month Change | 230.14% |
3 Month Change | 327.59% |
1 Year Change | 381.37% |
33 Year Change | -66.16% |
5 Year Change | -87.94% |
Change since IPO | -88.52% |
Recent News & Updates
Recent updates
We're Interested To See How Isofol Medical (STO:ISOFOL) Uses Its Cash Hoard To Grow
Jul 12An Intrinsic Calculation For Isofol Medical AB (publ) (STO:ISOFOL) Suggests It's 45% Undervalued
May 18Here's Why We're Not At All Concerned With Isofol Medical's (STO:ISOFOL) Cash Burn Situation
Nov 09Is Isofol Medical (STO:ISOFOL) In A Good Position To Deliver On Growth Plans?
May 12Market Sentiment Around Loss-Making Isofol Medical AB (publ) (STO:ISOFOL)
Apr 08Isofol Medical (STO:ISOFOL) Has Gifted Shareholders With A Fantastic 127% Total Return On Their Investment
Mar 03We Think Isofol Medical (STO:ISOFOL) Needs To Drive Business Growth Carefully
Jan 10Shareholder Returns
ISOFOL | SE Biotechs | SE Market | |
---|---|---|---|
7D | 37.8% | -5.0% | -7.2% |
1Y | 381.4% | 13.0% | 10.7% |
Return vs Industry: ISOFOL exceeded the Swedish Biotechs industry which returned 13.3% over the past year.
Return vs Market: ISOFOL exceeded the Swedish Market which returned 9.9% over the past year.
Price Volatility
ISOFOL volatility | |
---|---|
ISOFOL Average Weekly Movement | 28.3% |
Biotechs Industry Average Movement | 8.9% |
Market Average Movement | 5.9% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: ISOFOL's share price has been volatile over the past 3 months.
Volatility Over Time: ISOFOL's weekly volatility has increased from 19% to 28% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 4 | Petter Lindqvist | isofolmedical.com |
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.
Isofol Medical AB (publ) Fundamentals Summary
ISOFOL fundamental statistics | |
---|---|
Market cap | SEK 500.70m |
Earnings (TTM) | -SEK 31.16m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-16.1x
P/E RatioIs ISOFOL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ISOFOL income statement (TTM) | |
---|---|
Revenue | SEK 0 |
Cost of Revenue | SEK 32.54m |
Gross Profit | -SEK 32.54m |
Other Expenses | -SEK 1.37m |
Earnings | -SEK 31.16m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 21, 2024
Earnings per share (EPS) | -0.19 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did ISOFOL perform over the long term?
See historical performance and comparison